×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
GlobeNewswire
Completed oversubscribed $50 million private placement. First participant dosed in clinical trial at University of Chicago Medicine...
1 day ago
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst ...
Benzinga
Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney...
3 days ago
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024
MSN
Eledon Pharma (NASDAQ:ELDN) just reported results for the first quarter of 2024. Eledon Pharma reported earnings per share of -34 cents.
1 day ago
Could Eledon's Anti-CD40L Change Transplant Medicine?
In Vivo
Eledon Pharmaceuticals' CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant...
2 weeks ago
Eledon’s Antibody Aids First Gene-Edited, Pig-to-Human Kidney Transplant
BioSpace
Tegoprubart, Eledon Pharmaceuticals' experimental anti-CD40L antibody, was part of the immunosuppressive treatment regimen used following...
1 month ago
Will Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely?
Yahoo Finance
Eledon Pharmaceuticals didn't record any revenue over the last year, indicating that it's an early stage company still developing its business.
4 months ago
Eledon Pharmaceuticals Risks Shareholder Equity Dilution Amidst Private Placement and Potential Stock Issuances ...
Tipranks
Eledon Pharmaceuticals, Inc. (ELDN) has disclosed a new risk, in the Share Price & Shareholder Rights category. Eledon Pharmaceuticals, Inc. faces a...
1 month ago
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully
Simply Wall Street
In the last year, Eledon Pharmaceuticals burned through US$40m, which is just about equal to its US$41m market cap. That suggests the company...
1 month ago
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
GlobeNewswire
First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell...
3 days ago
Eledon Pharma completes first pig-to-human kidney transplant using Tegoprubart
Mugglehead Magazine
In a groundbreaking development in the field of transplantation, Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) announced the successful use of...
1 month ago